Traditional pharmacological treatments for diabetes, like oral antidiabetic drugs and insulin therapy, often encounter limitations, such as inadequate efficacy due to incorrect dosing, the first pass effect, P-glycoprotein efflux, decreased capability or impacts from drug ingestion, the absence of target particularity, a short duration of action, and adverse reactions, all of which can affect patient adherence and the comprehensive management of the condition [16,17]. The gene discussed is INS; the disease is diabetes mellitus.